Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation

PLoS ONE

Volumn 6, Issue 11, 2011, Pages

  Gong, Inna Y ^a   Schwarz, Ute I ^a   Crown, Natalie ^a   Dresser, George K ^a   Lazo Langner, Alejandro ^a,b   Zou, GuangYong ^b   Roden, Dan M ^c   Stein, C Michael ^c   Rodger, Marc ^d   Wells, Philip S ^d   Kim, Richard B ^a   Tirona, Rommel G ^a  

^a WESTERN UNIVERSITY   (Canada)

^b ROBARTS RESEARCH INSTITUTE   (Canada)

^c VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

WARFARIN; ANTICOAGULANT AGENT; CYP2C9 PROTEIN, HUMAN; CYP4F2 PROTEIN, HUMAN; CYTOCHROME P450; MENADIONE EPOXIDASE; MIXED FUNCTION OXIDASE; UNSPECIFIC MONOOXYGENASE; VITAMIN K GROUP;

ADULT; AGED; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; CYP2C9 GENE; CYP4F2 GENE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFICACY; DRUG RESPONSE; GENE; GENE IDENTIFICATION; GENETIC CORRELATION; GENOTYPE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MAJOR CLINICAL STUDY; PHARMACOGENETICS; PREDICTION; SENSITIVITY ANALYSIS; TREATMENT INDICATION; VENOUS THROMBOEMBOLISM; VKORC1 GENE; ALGORITHM; BLOOD CLOTTING; DOSE RESPONSE; DRUG EFFECT; FEMALE; GENE FREQUENCY; GENETICS; KIDNEY FUNCTION TEST; MALE; METABOLISM; MIDDLE AGED; PROSPECTIVE STUDY; TISSUE DISTRIBUTION;

ADULT; AGED; AGED, 80 AND OVER; ALGORITHMS; ANTICOAGULANTS; ARYL HYDROCARBON HYDROXYLASES; BLOOD COAGULATION; CYTOCHROME P-450 ENZYME SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED; MIXED FUNCTION OXYGENASES; PROSPECTIVE STUDIES; TISSUE DISTRIBUTION; VITAMIN K; WARFARIN; YOUNG ADULT;

EID: 81155137319     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0027808     Document Type: Article

References (55)

1. Ansell J, Hirsh J, Hylek E, Jacobson A, Crowther M, et al. (2008) Pharmacology and management of the vitamin K antagonists: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 160S-198S.
2. Landefeld CS, Beyth RJ, (1993) Anticoagulant-related bleeding: clinical epidemiology, prediction, and prevention. Am J Med 95: 315-328.
3. Fasco MJ, Principe LM, (1982) R- and S-Warfarin inhibition of vitamin K and vitamin K 2,3-epoxide reductase activities in the rat. J Biol Chem 257: 4894-4901.
4. Kaminsky LS, Zhang ZY, (1997) Human P450 metabolism of warfarin. Pharmacol Ther 73: 67-74.
5. Wadelius M, Chen LY, Eriksson N, Bumpstead S, Ghori J, et al. (2007) Association of warfarin dose with genes involved in its action and metabolism. Hum Genet 121: 23-34.
6. Juurlink DN, (2007) Drug interactions with warfarin: what clinicians need to know. CMAJ 177: 369-371.
7. Kamali F, Khan TI, King BP, Frearson R, Kesteven P, et al. (2004) Contribution of age, body size, and CYP2C9 genotype to anticoagulant response to warfarin. Clin Pharmacol Ther 75: 204-212.
8. Sconce EA, Khan TI, Wynne HA, Avery P, Monkhouse L, et al. (2005) The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements: proposal for a new dosing regimen. Blood 106: 2329-2333.
9. Wynne H, Cope L, Kelly P, Whittingham T, Edwards C, et al. (1995) The influence of age, liver size and enantiomer concentrations on warfarin requirements. Br J Clin Pharmacol 40: 203-207.
10. Herman D, Locatelli I, Grabnar I, Peternel P, Stegnar M, et al. (2005) Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose. Pharmacogenomics J 5: 193-202.
11. Nelson E, (1961) Kinetics of drug absorption, distribution, metabolism, and excretion. J Pharm Sci 50: 181-192.
12. O'Reilly RA, Aggeler PM, Leong LS, (1963) Studies on the Coumarin Anticoagulant Drugs: The Pharmacodynamics of Warfarin in Man. J Clin Invest 42: 1542-1551.
13. Gage BF, Eby C, Milligan PE, Banet GA, Duncan JR, et al. (2004) Use of pharmacogenetics and clinical factors to predict the maintenance dose of warfarin. Thromb Haemost 91: 87-94.
14. Loebstein R, Yonath H, Peleg D, Almog S, Rotenberg M, et al. (2001) Interindividual variability in sensitivity to warfarin--Nature or nurture? Clin Pharmacol Ther 70: 159-164.
15. Cain D, Hutson SM, Wallin R, (1997) Assembly of the warfarin-sensitive vitamin K 2,3-epoxide reductase enzyme complex in the endoplasmic reticulum membrane. J Biol Chem 272: 29068-29075.
16. Rieder MJ, Reiner AP, Gage BF, Nickerson DA, Eby CS, et al. (2005) Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med 352: 2285-2293.
17. Yuan HY, Chen JJ, Lee MT, Wung JC, Chen YF, et al. (2005) A novel functional VKORC1 promoter polymorphism is associated with inter-individual and inter-ethnic differences in warfarin sensitivity. Hum Mol Genet 14: 1745-1751.
18. Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, et al. (2009) A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. PLoS Genet 5: e1000433.
19. McDonald MG, Rieder MJ, Nakano M, Hsia CH, Rettie AE, (2009) Cyp4f2 Is a Vitamin K1 Oxidase: an Explanation for Altered Warfarin Dose in Carriers of the V433m Variant. Mol Pharmacol.
20. Borgiani P, Ciccacci C, Forte V, Sirianni E, Novelli L, et al. (2009) CYP4F2 genetic variant (rs2108622) significantly contributes to warfarin dosing variability in the Italian population. Pharmacogenomics 10: 261-266.
21. Caldwell MD, Awad T, Johnson JA, Gage BF, Falkowski M, et al. (2008) CYP4F2 genetic variant alters required warfarin dose. Blood 111: 4106-4112.
22. Karlson B, Leijd B, Hellstrom K, (1986) On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment. Acta Med Scand 220: 347-350.
23. Pedersen FM, Hamberg O, Hess K, Ovesen L, (1991) The effect of dietary vitamin K on warfarin-induced anticoagulation. J Intern Med 229: 517-520.
24. Cushman M, Booth SL, Possidente CJ, Davidson KW, Sadowski JA, et al. (2001) The association of vitamin K status with warfarin sensitivity at the onset of treatment. Br J Haematol 112: 572-577.
25. Gage BF, Eby C, Johnson JA, Deych E, Rieder MJ, et al. (2008) Use of pharmacogenetic and clinical factors to predict the therapeutic dose of warfarin. Clin Pharmacol Ther 84: 326-331.
26. Klein TE, Altman RB, Eriksson N, Gage BF, Kimmel SE, et al. (2009) Estimation of the warfarin dose with clinical and pharmacogenetic data. N Engl J Med 360: 753-764.
27. Takahashi H, Ishikawa S, Nomoto S, Nishigaki Y, Ando F, et al. (2000) Developmental changes in pharmacokinetics and pharmacodynamics of warfarin enantiomers in Japanese children. Clin Pharmacol Ther 68: 541-555.
28. Hamberg AK, Dahl ML, Barban M, Scordo MG, Wadelius M, et al. (2007) A PK-PD model for predicting the impact of age, CYP2C9, and VKORC1 genotype on individualization of warfarin therapy. Clin Pharmacol Ther 81: 529-538.
29. Gong IY, Tirona RG, Schwarz UI, Crown N, Dresser GK, et al. (2011) Prospective evaluation of a pharmacogenetics-guided warfarin loading and maintenance dose regimen for initiation of therapy. Blood 118: 3163-3171.
30. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, et al. (2009) A new equation to estimate glomerular filtration rate. Ann Intern Med 150: 604-612.
31. Levy G, Mager DE, Cheung WK, Jusko WJ, (2003) Comparative pharmacokinetics of coumarin anticoagulants L: Physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man. J Pharm Sci 92: 985-994.
32. Wagner JG, Welling PG, Lee KP, Walker JE, (1971) In vivo and in vitro availability of commercial warfarin tablets. J Pharm Sci 60: 666-677.
33. Jusko WJ, Ko HC, (1994) Physiologic indirect response models characterize diverse types of pharmacodynamic effects. Clin Pharmacol Ther 56: 406-419.
34. Dayneka NL, Garg V, Jusko WJ, (1993) Comparison of four basic models of indirect pharmacodynamic responses. J Pharmacokinet Biopharm 21: 457-478.
35. Cao YG, Liu XQ, Chen YC, Hao K, Wang GJ, (2007) Warfarin maintenance dose adjustment with indirect pharmacodynamic model in rats. Eur J Pharm Sci 30: 175-180.
36. Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, et al. (2006) Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130: 1793-1806.
37. Tirona RG, Leake BF, Merino G, Kim RB, (2001) Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 276: 35669-35675.
38. Hallgren KW, Qian W, Yakubenko AV, Runge KW, Berkner KL, (2006) r-VKORC1 expression in factor IX BHK cells increases the extent of factor IX carboxylation but is limited by saturation of another carboxylation component or by a shift in the rate-limiting step. Biochemistry 45: 5587-5598.
39. Scordo MG, Pengo V, Spina E, Dahl ML, Gusella M, et al. (2002) Influence of CYP2C9 and CYP2C19 genetic polymorphisms on warfarin maintenance dose and metabolic clearance. Clin Pharmacol Ther 72: 702-710.
40. Lenzini P, Wadelius M, Kimmel S, Anderson JL, Jorgensen AL, et al. (2010) Integration of genetic, clinical, and INR data to refine warfarin dosing. Clin Pharmacol Ther 87: 572-578.
41. Kovacs MJ, Rodger M, Anderson DR, Morrow B, Kells G, et al. (2003) Comparison of 10-mg and 5-mg warfarin initiation nomograms together with low-molecular-weight heparin for outpatient treatment of acute venous thromboembolism. A randomized, double-blind, controlled trial. Ann Intern Med 138: 714-719.
42. Lazo-Langner A, Monkman K, Kovacs MJ, (2009) Predicting warfarin maintenance dose in patients with venous thromboembolism based on the response to a standardized warfarin initiation nomogram. J Thromb Haemost 7: 1276-1283.
43. Hylek EM, Evans-Molina C, Shea C, Henault LE, Regan S, (2007) Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation 115: 2689-2696.
44. McMahan DA, Smith DM, Carey MA, Zhou XH, (1998) Risk of major hemorrhage for outpatients treated with warfarin. J Gen Intern Med 13: 311-316.
45. Willey VJ, Bullano MF, Hauch O, Reynolds M, Wygant G, et al. (2004) Management patterns and outcomes of patients with venous thromboembolism in the usual community practice setting. Clin Ther 26: 1149-1159.
46. Garcia DA, Lopes RD, Hylek EM, (2010) New-onset atrial fibrillation and warfarin initiation: High risk periods and implications for new antithrombotic drugs. Thromb Haemost 104.
47. Limdi NA, Beasley TM, Baird MF, Goldstein JA, McGwin G, et al. (2009) Kidney function influences warfarin responsiveness and hemorrhagic complications. J Am Soc Nephrol 20: 912-921.
48. Limdi NA, Limdi MA, Cavallari L, Anderson AM, Crowley MR, et al. (2010) Warfarin dosing in patients with impaired kidney function. Am J Kidney Dis 56: 823-831.
49. Garcia D, Regan S, Crowther M, Hughes RA, Hylek EM, (2005) Warfarin maintenance dosing patterns in clinical practice: implications for safer anticoagulation in the elderly population. Chest 127: 2049-2056.
50. Kerin NZ, Blevins RD, Goldman L, Faitel K, Rubenfire M, (1988) The incidence, magnitude, and time course of the amiodarone-warfarin interaction. Arch Intern Med 148: 1779-1781.
51. Sanoski CA, Bauman JL, (2002) Clinical observations with the amiodarone/warfarin interaction: dosing relationships with long-term therapy. Chest 121: 19-23.
52. Schelleman H, Bilker WB, Brensinger CM, Han X, Kimmel SE, et al. (2008) Warfarin with fluoroquinolones, sulfonamides, or azole antifungals: interactions and the risk of hospitalization for gastrointestinal bleeding. Clin Pharmacol Ther 84: 581-588.
53. Linder MW, Bon Homme M, Reynolds KK, Gage BF, Eby C, et al. (2009) Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy. Clin Chem 55: 1861-1868.
54. Crosier MD, Peter I, Booth SL, Bennett G, Dawson-Hughes B, et al. (2009) Association of sequence variations in vitamin K epoxide reductase and gamma-glutamyl carboxylase genes with biochemical measures of vitamin K status. J Nutr Sci Vitaminol (Tokyo) 55: 112-119.
55. Wells PS, Le Gal G, Tierney S, Carrier M, (2009) Practical application of the 10-mg warfarin initiation nomogram. Blood Coagul Fibrinolysis 20: 403-408.